WO2001021192A3 - Methods for diagnosis and therapy of hematological and virus-associated malignancies - Google Patents

Methods for diagnosis and therapy of hematological and virus-associated malignancies Download PDF

Info

Publication number
WO2001021192A3
WO2001021192A3 PCT/US2000/026110 US0026110W WO0121192A3 WO 2001021192 A3 WO2001021192 A3 WO 2001021192A3 US 0026110 W US0026110 W US 0026110W WO 0121192 A3 WO0121192 A3 WO 0121192A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
methods
hematological
diagnosis
therapy
Prior art date
Application number
PCT/US2000/026110
Other languages
French (fr)
Other versions
WO2001021192A2 (en
Inventor
Alexander Gaiger
Martin A Cheever
Original Assignee
Corixa Corp
Alexander Gaiger
Martin A Cheever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Alexander Gaiger, Martin A Cheever filed Critical Corixa Corp
Priority to AU77103/00A priority Critical patent/AU7710300A/en
Priority to CA002383615A priority patent/CA2383615A1/en
Priority to EP00966815A priority patent/EP1214595A2/en
Publication of WO2001021192A2 publication Critical patent/WO2001021192A2/en
Publication of WO2001021192A3 publication Critical patent/WO2001021192A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.
PCT/US2000/026110 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies WO2001021192A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU77103/00A AU7710300A (en) 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies
CA002383615A CA2383615A1 (en) 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies
EP00966815A EP1214595A2 (en) 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40444399A 1999-09-22 1999-09-22
US09/404,443 1999-09-22

Publications (2)

Publication Number Publication Date
WO2001021192A2 WO2001021192A2 (en) 2001-03-29
WO2001021192A3 true WO2001021192A3 (en) 2001-08-16

Family

ID=23599624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026110 WO2001021192A2 (en) 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Country Status (4)

Country Link
EP (1) EP1214595A2 (en)
AU (1) AU7710300A (en)
CA (1) CA2383615A1 (en)
WO (1) WO2001021192A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1490801A (en) * 1999-11-15 2001-05-30 University Of Southern California Targeted delivery of therapeutic and diagnostic moieties
AU2744201A (en) * 1999-12-29 2001-07-09 Corixa Corporation Murine neu sequences and methods of use therefor
ATE441433T1 (en) 2000-05-19 2009-09-15 Genentech Inc GENETIC DETECTION METHOD TO IMPROVE THE PROBABILITY OF AN EFFECTIVE RESPONSE TO CANCER THERAPY WITH A HERITAGE ANTAGONIST
WO2002013847A2 (en) * 2000-08-14 2002-02-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
CA2518716A1 (en) * 2003-03-11 2005-01-13 Dana-Farber Cancer Institute Inhibition of viral pathogenesis
CN101141981A (en) 2005-01-21 2008-03-12 健泰科生物技术公司 Fixed dosing of her antibodies
EP2399605A1 (en) 2005-02-23 2011-12-28 Genentech, Inc. Extending time to disease progression or survival in cancer patients
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
KR20130080871A (en) 2009-03-20 2013-07-15 제넨테크, 인크. Bispecific anti-her antibodies
CN102421448A (en) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Modulators for her2 signaling in her2 expressing patients with gastric cancer
SI2536748T1 (en) 2010-02-18 2014-12-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
BR112014003431A2 (en) 2011-08-17 2017-06-13 Genentech Inc antibody, nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, pharmaceutical agent, use of the antibody, method of treating an individual who has cancer, and time-lapse method for tumor recurrence
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
BR112014024017A8 (en) 2012-03-27 2017-07-25 Genentech Inc METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS
CN104813168B (en) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 Need the identification of the patient of PD L1 inhibitor composite treatments
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5876712A (en) * 1993-03-17 1999-03-02 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5876712A (en) * 1993-03-17 1999-03-02 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAWASAKI ERNEST S: "The polymerase chain reaction: Its use in the molecular characterization and diagnosis of cancers.", CANCER INVESTIGATION, vol. 10, no. 5, 1992, pages 417 - 429, XP000982780, ISSN: 0735-7907 *
THOMAS H ET AL: "An inbred colony of oncogene transgenic mice: Diversity of tumours and potential as a therapeutic model.", BRITISH JOURNAL OF CANCER, vol. 73, no. 1, 1996, pages 65 - 72, XP000982716, ISSN: 0007-0920 *
WU MING-SHIANG ET AL: "Epstein-Barr virus-associated gastric carcinomas: Relation to H. pylori infection and genetic alterations.", GASTROENTEROLOGY, vol. 118, no. 6, June 2000 (2000-06-01), pages 1031 - 1038, XP000982766, ISSN: 0016-5085 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

Also Published As

Publication number Publication date
AU7710300A (en) 2001-04-24
WO2001021192A2 (en) 2001-03-29
EP1214595A2 (en) 2002-06-19
CA2383615A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
WO2002013847A3 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001021192A3 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
ZA99693B (en) Compounds for therapy and diagnosis of lung cancer and methods for their use.
HK1020167A1 (en) Oxa acids and related compounds for treating skin conditions.
AU3783599A (en) Non-invasive methods to detect prostate cancer
HUP0201757A3 (en) Compositoins and methods for the therapy and diagnosis of lung cancer
AU2212299A (en) Compositions and methods for the treatment of tumor
ATE242238T1 (en) QUINOLINE AND QUINAZOLINE COMPOUNDS OF THERAPEUTIC UTILITY, PARTICULARLY FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA
ID21529A (en) METHODS AND COMPOSITIONS FOR TUMOR TREATMENT, PREVENTION, RELATIONSHIP RELATED TO TUMORS AND COCOEX
AU7012496A (en) Compounds and methods for treatment and diagnosis of prostate cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
AU3552399A (en) Recombinant poliovirus for the treatment of cancer
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
EP1015038A4 (en) Methods for the detection, treatment, and prevention of neurodegeneration
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
GB9811598D0 (en) Diagnosis and treatment of cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
ZA974730B (en) Treatment of vascular lesions.
PL338726A1 (en) Improved treatment of hides
ZA974421B (en) Method of improving skin condition.
EP1250145A4 (en) C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
EP1109830A4 (en) Mc4-r as target for the identification of compounds used to treat drug addiction
AU3031097A (en) Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2383615

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000966815

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000966815

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000966815

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP